Abstract: A disclosed computer-implemented method may include partitioning, based on a social graph representative of social connections among a plurality of users of a social networking system, the plurality of users into a plurality of user buckets. Each user bucket may include at least one user of the social networking system. The method may further include selecting a set of user buckets from the plurality of user buckets, assigning the set of user buckets to a data center included in a networking infrastructure, and routing data sent from a user device associated with a user included in the set of user buckets to the data center. Various other methods, systems, and computer-readable media are also disclosed.

Abstract: A method of unambiguous identification and authentication of products for the purpose of better recognition of product forgeries and controlling product piracy, including applying to/into the product an identification substance admixture which contains paramagnetic phases or identifying a product which contains an identification substance admixture containing paramagnetic phases and has an ESR fingerprint spectrum that permits unambiguous identification of the product. Such an ESR fingerprint spectrum is easily measurable, but can be copied or forged only with difficulty. The method relates to an individualizable “femto tag” for femto ledgers and forms an important interface for what are known as “Internet of Things” (IOT).

Abstract: A computing device executing a chatbot application stores primary classification data in a memory; the primary classification data includes records each containing a primary class attribute and corresponding primary response data. The device obtains and stores, from a central repository, a copy of secondary classification data including records each containing a secondary class attribute and corresponding secondary response data. The device receives a message from a client device, and determines whether the message matches any of the primary class attributes. When the message does not match any of the primary class attributes, the device determines whether the message matches any of the secondary class attributes. Based on a match between the message and one of the secondary class attributes, the device selects secondary response data corresponding to the one of the secondary class attributes; and transmits a response to the client device, including the selected secondary response data.

Abstract: Described herein are wearable devices comprising a base coupled to a user, and a microneedle array supported by a base.

Abstract: A disclosed computer-implemented method may include receiving, via a monitoring infrastructure that monitors an operational state of a networking infrastructure, data representative of the operational state of the networking infrastructure during a period of time. The networking infrastructure may include (1) a plurality of data centers, and (2) at least one point-of-presence (POP) edge node. The method may also include (1) accessing data representative of a set of predefined policies associated with the networking infrastructure, and (2) based on the data representative of the operational state (a) determining a set of edge load factors associated with the edge node, and (b) generating, via a linear solver and further based the set of edge load factors associated with the edge node and the set of predefined policies associated with the networking infrastructure, a routing table for the POP edge node. Various other methods, systems, and computer-readable media are also disclosed.

Abstract: Described herein are microneedle arrays for delivery of medicinal formulations. The microneedle arrays includes an anchoring system for securing the microneedle arrays to the skin for a period of time, e.g., a treatment period. The microneedles in the array also may include a coating, such as a lubricious coating for ease of puncturing/penetrating the skin or anti-microbial agents.

Abstract: An injection solution contains an organic solvent, a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent and a pharmaceutical active ingredient which is non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups. The content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.

Abstract: The disclosure is directed in part to extended release compositions that include hydroxy progesterone caproate. For example, provided herein is a therapeutic microparticle composition comprising a plurality of microparticles, wherein the microparticles each comprise poly (lactide-co-glycolide) and hydroxyprogesterone caproate.

Abstract: An injection solution can be used in a pharmaceutical dosage formulation. The injection solution includes an organic solvent, a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent, and a pharmaceutical active ingredient, which is a non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, and which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups, where a content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.

Abstract: An injection solution can be used in a pharmaceutical dosage formulation. The injection solution includes an organic solvent, a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent, and a pharmaceutical active ingredient, which is a non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, and which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups, where a content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.

Abstract: A computing device executing a chatbot application stores primary classification data in a memory; the primary classification data includes records each containing a primary class attribute and corresponding primary response data. The device obtains and stores, from a central repository, a copy of secondary classification data including records each containing a secondary class attribute and corresponding secondary response data. The device receives a message from a client device, and determines whether the message matches any of the primary class attributes. When the message does not match any of the primary class attributes, the device determines whether the message matches any of the secondary class attributes. Based on a match between the message and one of the secondary class attributes, the device selects secondary response data corresponding to the one of the secondary class attributes; and transmits a response to the client device, including the selected secondary response data.

Abstract: The described invention provides a biodegradable, biocompatible delivery system of flowable sustained release microparticulate composition of a substantially pure crystalline form of a bioactive agent such as, for example, nimodipine, a process of preparing a therapeutic form of a substantially pure crystalline form of the bioactive agent and a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury.

Abstract: Described herein are methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems via direct modification of the isoelectric point and/or net charge of the bioactive agent.

Abstract: Described herein are methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems via direct modification of the isoelectric point and/or net charge of the bioactive agent.

Abstract: The described invention provides a biodegradable, biocompatible delivery system of flowable sustained release microparticulate composition of a substantially pure crystalline form of a bioactive agent such as, for example, nimodipine, a process of preparing a therapeutic form of a substantially pure crystalline form of the bioactive agent and a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury.

Abstract: The described invention provides a biodegradable, biocompatible delivery system of flowable sustained release microparticulate composition of a substantially pure crystalline form of a bioactive agent such as, for example, nimodipine, a process of preparing a therapeutic form of a substantially pure crystalline form of the bioactive agent and a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury.

Abstract: Provided herein are water-soluble polymer conjugates and polymer-based compositions of non-steroidal anti-inflammatory drugs. Also provided are methods for synthesizing and administering such conjugates and compositions.

Abstract: The described invention provides a biodegradable, biocompatible delivery system of flowable sustained release microparticulate composition of a substantially pure crystalline form of a bioactive agent such as, for example, nimodipine, a process of preparing a therapeutic form of a substantially pure crystalline form of the bioactive agent and a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury.

Abstract: Described herein are methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems via direct modification of the isoelectric point and/or net charge of the bioactive agent.

Abstract: The present invention relates to polymeric microparticles comprising a therapeutic polypeptide along with a redox reagent. Also disclosed are methods of using the microparticles, including methods of using the microparticles for delivery of the therapeutic polypeptide to a subject in need thereof.